Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
Huayang Liu,Javad Golji,Lauren K. Brodeur,Franklin S. Chung,Julie T. Chen,Rosalie S. deBeaumont,Caroline P. Bullock,Michael D. Jones,Grainne Kerr,Li Li,Daniel P. Rakiec,Michael R. Schlabach,Sosathya Sovath,Joseph D. Growney,Raymond A. Pagliarini,David A. Ruddy,Kenzie D. MacIsaac,Joshua M. Korn,E. Robert McDonald
DOI: https://doi.org/10.1038/s41591-018-0302-5
IF: 82.9
2018-12-17
Nature Medicine
Abstract:Interferons (IFNs) are cytokines that play a critical role in limiting infectious and malignant diseases1–4. Emerging data suggest that the strength and duration of IFN signaling can differentially impact cancer therapies, including immune checkpoint blockade5–7. Here, we characterize the output of IFN signaling, specifically IFN-stimulated gene (ISG) signatures, in primary tumors from The Cancer Genome Atlas. While immune infiltration correlates with the ISG signature in some primary tumors, the existence of ISG signature-positive tumors without evident infiltration of IFN-producing immune cells suggests that cancer cells per se can be a source of IFN production. Consistent with this hypothesis, analysis of patient-derived tumor xenografts propagated in immune-deficient mice shows evidence of ISG-positive tumors that correlates with expression of human type I and III IFNs derived from the cancer cells. Mechanistic studies using cell line models from the Cancer Cell Line Encyclopedia that harbor ISG signatures demonstrate that this is a by-product of a STING-dependent pathway resulting in chronic tumor-derived IFN production. This imposes a transcriptional state on the tumor, poising it to respond to the aberrant accumulation of double-stranded RNA (dsRNA) due to increased sensor levels (MDA5, RIG-I and PKR). By interrogating our functional short-hairpin RNA screen dataset across 398 cancer cell lines, we show that this ISG transcriptional state creates a novel genetic vulnerability. ISG signature-positive cancer cells are sensitive to the loss of ADAR, a dsRNA-editing enzyme that is also an ISG. A genome-wide CRISPR genetic suppressor screen reveals that the entire type I IFN pathway and the dsRNA-activated kinase, PKR, are required for the lethality induced by ADAR depletion. Therefore, tumor-derived IFN resulting in chronic signaling creates a cellular state primed to respond to dsRNA accumulation, rendering ISG-positive tumors susceptible to ADAR loss.
biochemistry & molecular biology,cell biology,medicine, research & experimental